RxDoctor Payments Data

Michael Stewart, MD

Ophthalmology · Jacksonville, FLNPI 1417947268

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $39,677 of the $40,092 with a category attached, or 99.0%. Grifols, S.A. accounts for 81.8% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $35,679 and has fallen 96.5% since, to $1,263 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$40,092in general payments, 2019–2025

Across 13 payments — averaging $3084.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Grifols, S.A.$33K
  • Biogen$6K
  • Regeneron$1K
  • Regeneron Healthcare Solutions, Inc.$114
  • Amgen$107
  • Astellas Pharma US Inc$60
  • plus $115 from 4 others
$45,482in research payments, 2019–2025

Across 4 payments — averaging $11,370 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$39K
  • Novartis$6K
  • AbbVie$649

What the payments were for

  • Consulting fees$39,67799%
  • Food & beverage$4151%

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,092 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida →

Medicare billing

Part B allowed, 2024
$2,263,442
Medicare patients
1,234
Services billed
12,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine11$14,747
Prednisolone Acetate246$8,090
Tobramycin-DexamethasoneTobramycin/Dexamethasone69$2,904
Difluprednate15$2,595
Latanoprost231$1,838
Ofloxacin112$1,131
Timolol Maleate52$1,003
Brimonidine Tartrate47$414
Ketorolac Tromethamine34$331
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat17$298
Dorzolamide Hcl23$275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$28$14,74711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Jacksonville

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →